Publications by authors named "I Ghemlas"
Congenital amegakaryocytic thrombocytopenia is a rare, inherited bone marrow failure syndrome. Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. In this retrospective study, we analysed 66 patients with allo-HSCT, reported in the European Society for Blood and Marrow Transplantation (EBMT) registry.
View Article and Find Full Text PDFMatched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study.
Haematologica
July 2024
Article Synopsis
- In kids with acute myeloid leukemia (AML) who don't have a sibling that is a perfect match for a donor, doctors can use other types of donors.
- This study looked at how well kids with AML did after receiving stem cell transplants from two different types of donors from 2011 to 2021.
- It found that while one type of transplant (from a haploidentical donor) had a higher risk of certain complications, both transplant types showed similar success rates in keeping the leukemia away and overall survival after two years.
Hematopoietic stem cell transplantation (HSCT) has been considered curative for children with high-risk acute leukemia (ALL), offering better survival. Short tandem repeat has been used as a marker of chimerism status after HSCT. The appearance of recipient cells >1% post-allogeneic stem cell transplant is defined as mixed chimerism (MC).
View Article and Find Full Text PDFObjectives: Allogeneic hematopoietic cell transplantation (Allo-HCT) is a curative option for children with various malignant and non-malignant diseases. Most reports studied all age groups amongst children. Herein we analyzed our data in children transplanted at or less than 2-years of age.
View Article and Find Full Text PDF